Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Bromocriptine, a dopamine agonist, is now an accepted primary therapeutic agent for patients with prolactinomas and other pituitary adenomas. However, the mechanism by which bromocriptine decreases elevated serum levels of prolactin or growth hormone and shrinks tumors by diminishing tumor cell size is not clear. Recently, we obtained bromocriptine induced apoptosis in murine ACTH-secreting pituitary adenoma (AtT-20) cells, based on DNA fragmentation assay and cell cycle analysis (unpublished data). In this study, we demonstrate that enforced expression of bcl-2 gene in AtT-20 cells by the MPZenNeo(bcl-2) retroviral gene transfer increased resistance to apoptosis induced by bromocriptine.


Journal article


International Journal of Oncology

Publication Date





187 - 191